Leal Therapeutics

Leal Therapeutics

  • Founded: 2021
  • Location: Worcester, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: CNS diseases
  • Drug types: NEU
  • Lead product: Undisclosed
  • Product link: https://lealtx.com/
  • Funding: not disclosed



job board

Short description:

CNS Therapies

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Leal therapeutics is developing novel therapeutics for central nervous system disorders. The company has yet to reveal much information about their therapeutics and scientific approach. The company’s CEO, Asa Abeliovich, has noted that Leal will work on oligonucleotide-based therapeutics and have a broad focus that includes psychiatric and neurodegenerative diseases. One of the key challenges and thus innovations for Leal will be oligonucleotide delivery within the brain. Leal will target patients who, based on genetic and other data, are likely to respond positively to specific drugs. During treatment, Leal plans to monitor biomarker data to determine the effectiveness of their therapeutics. Leal Therapeutics is developing novel small molecule therapies that target the Wnt signaling pathway, which is a key regulator of cell growth and differentiation. The Wnt signaling pathway is involved in a wide range of biological processes, including development, tissue repair, and stem cell maintenance. However, dysregulation of the Wnt signaling pathway can lead to a variety of diseases, including cancer, inflammatory diseases, and fibrotic diseases. Leal Therapeutics' Wnt pathway modulators are designed to selectively target specific components of the Wnt signaling pathway, which allows for the development of therapies that are both effective and well-tolerated.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com